A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors

Bo Gao, Mark Voskoboynik, Adam Cooper, Kate Wilkinson, Siao Hoon, Chih‐Yi Hsieh, Suixiong Cai, Ye Edward Tian, Jun Bao, Ning Ma, Chen Wang, Ming Zhang, Baoyue Li, Mingchuan Guo, Ruiyu Zhou, Xiaozhu Wang, Cong Xu, Paul de Souza

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Background: Senaparib is a novel, selective poly(ADP-ribose) polymerase-1/2 inhibitor with strong antitumor activity in preclinical studies. This first-in-human, phase 1, dose-escalation study examined the safety and preliminary efficacy of senaparib in patients with advanced solid tumors. Methods: Patients with advanced solid tumors were enrolled from three centers in Australia, using a conventional 3 + 3 design. Dose-escalation cohorts continued until the maximum tolerated dose or a recommended phase 2 dose was determined. Patients received one dose of oral senaparib and, if no dose-limiting toxicity occurred within 7 days, they received senaparib once daily in 3-week cycles. The primary end points were safety and tolerability. Results: Thirty-nine patients were enrolled at 10 dose levels ranging from 2 to 150 mg. No dose-limiting toxicities were observed in any cohort. Most treatment-emergent adverse events were grade 1–2 (91%). Seven patients (17.9%) reported hematologic treatment-emergent adverse events. Treatment-related adverse events occurred in eight patients (20.5%), and the most frequent was nausea (7.7%). Two deaths were reported after the end of study treatment, one of which was considered a complication from senaparib-related bone marrow failure. Pharmacokinetic analysis indicated that senaparib the accumulation index was 1.06–1.67, and absorption saturation was 80–150 mg daily. In 22 patients with evaluable disease, the overall response rate was 13.6%, and the disease control rate was 81.8%. The overall response rate was 33.3% for the BRCA mutation-positive subgroup and 6.3% for the nonmutated subgroup. Conclusions: Senaparib was well tolerated in Australian patients with advanced solid tumors, with encouraging signals of antitumor activity. The recommended phase 2 dose for senaparib was determined to be 100 mg daily. ClinicalTrials.gov ID: NCT03507543.

Original languageEnglish
Pages (from-to)1041-1050
Number of pages10
JournalCancer
Volume129
Issue number7
Publication statusPublished - 1 Apr 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

Open Access - Access Right Statement

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. © 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

Keywords

  • recommended phase 2 dose
  • senaparib
  • PARP inhibitor
  • Australia
  • BRCA mutation
  • solid tumors

Fingerprint

Dive into the research topics of 'A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors'. Together they form a unique fingerprint.

Cite this